Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|5|487-495

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.5, 2008-02, pp. : 487-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes

By  

Current Drug Targets, Vol. 8, Iss. 10, 2007-10 ,pp. : 1138-1143

Bentham Science Publishers

Access to resources Recommend Favorite

Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target

By  

Current Medicinal Chemistry, Vol. 13, Iss. 17, 2006-07 ,pp. : 1971-1978

Bentham Science Publishers

Access to resources Recommend Favorite

Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders

By  

Current Pharmaceutical Design, Vol. 13, Iss. 27, 2007-09 ,pp. : 2832-2836

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 939-939

Bentham Science Publishers

Access to resources Recommend Favorite